In this free webinar, learn how digital cognitive assessments can support participant identification and pre-screening in early Alzheimer's disease clinical trials. The featured speaker will discuss case-finding strategies, participant enrichment and the characteristics that make cognitive measures suitable for screening workflows. Attendees will also explore the opportunities and limitations of digital cognitive assessments to improve recruitment efficiency, reduce screen failures and support earlier trial enrollment.
TORONTO, Nov. 18, 2026 /PRNewswire/ -- As Alzheimer's disease (AD) clinical trials are conducted earlier in the disease continuum, efficient approaches to identify appropriate participants are increasingly important. While biomarkers remain essential for confirming underlying AD pathology, large-scale recruitment efforts require practical methods to identify individuals most likely to meet study clinical eligibility criteria.
Digital cognitive assessments offer a scalable and flexible approach to case finding for site- and community-based recruitment settings, as well as for remote use. Real-time scoring, centralized decision-making and remote administration capabilities enable cognitive data to be incorporated into screening workflows, helping researchers identify individuals who are more likely to demonstrate cognitive impairment, be at elevated risk of progression or exhibit biomarker evidence of AD pathology. However, optimal case finding using digital cognitive assessments requires clearly defined and broadly understood decision-making criteria and recommended actions.
This webinar will review key considerations for designing cognitive pre-screening strategies used in clinical trials of preclinical and symptomatic AD. Drawing on examples from clinical trial and observational research, the featured speaker will discuss how digital cognitive assessments can support recruitment efficiency, the characteristics that make cognitive measures suitable for case-finding applications, the conditions necessary for optimal decision making and evidence supporting the use of digital cognitive assessments in participant identification and enrichment strategies.
Register for this webinar to learn how digital cognitive assessments can support effective pre-screening strategies, improve participant identification and enhance recruitment efficiency in early Alzheimer's disease clinical trials.
Join Karra Harrington, PhD, Principal Scientist, Digital Endpoint Specialist, Cogstate, for the live webinar on Tuesday, December 8, 2026, at 11am EST (5pm CET / EU-Central).
For more information, or to register for this event, visit Digital Cognitive Assessments for Early Alzheimer's Clinical Trials.
ABOUT XTALKS
Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.
Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.
To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/
Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]
SOURCE Xtalks


Share this article